Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer

BACKGROUND: Eribulin mesylate (eribulin) is currently indicated for treatment of locally advanced or metastatic breast cancer (MBC). It is a cytotoxic agent with unique mechanisms that suppress epithelial-mesenchymal transition (EMT) of cancer cells. On the other hand, Tumor-infiltrating lymphocytes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Shinichiro, Asano, Yuka, Goto, Wataru, Takada, Koji, Takahashi, Katsuyuki, Noda, Satoru, Takashima, Tsutomu, Onoda, Naoyoshi, Tomita, Shuhei, Ohsawa, Masahiko, Hirakawa, Kosei, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293550/
https://www.ncbi.nlm.nih.gov/pubmed/28166544
http://dx.doi.org/10.1371/journal.pone.0170634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293550/
https://www.ncbi.nlm.nih.gov/pubmed/28166544
http://dx.doi.org/10.1371/journal.pone.0170634

Ejemplares similares